Impact of Bariatric Surgery on Medication Efficacy: an Analysis of World Health Organization Pharmacovigilance Data.
Bariatric surgery
Medication
Pharmacodynamic
Pharmacovigilance
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
08
12
2020
accepted:
26
01
2021
revised:
21
01
2021
pubmed:
13
2
2021
medline:
21
5
2021
entrez:
12
2
2021
Statut:
ppublish
Résumé
Bariatric surgery is the most effective treatment of severe obesity. However, this surgery can have an impact on the bioavailability and metabolism of oral drugs as it modifies absorption, intestinal, and hepatic metabolism, and efflux transporter activity. The clinical impact of such modifications often remains unknown. To investigate, we extracted and summarized all reports of changes in drug efficacy associated with bariatric surgery registered in the WHO pharmacovigilance database. We identified 165 drug reports affecting 128 patients. The majority involved gastric bypass surgery (77.3%). Most reports concerned drug ineffectiveness (74.7%). The most frequent modifications concerned psychotropic drugs with a reduction in efficacy. This study underlines the urgent need for more research to better characterize the impact of bariatric surgery on drug pharmacokinetics and clinical efficacy.
Identifiants
pubmed: 33576906
doi: 10.1007/s11695-021-05258-4
pii: 10.1007/s11695-021-05258-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2823-2830Références
Ames GE, Maynard JR, Collazo-Clavell ML, et al. Rethinking Patient and medical professional perspectives on bariatric surgery as a medically necessary treatment. Mayo Clin Proc. 2020;95(3):527–40.
doi: 10.1016/j.mayocp.2019.09.019
McLachlan LA, Chaar BB, Um IS. Pharmacokinetic changes post-bariatric surgery: a scoping review. Obes Rev Off J Int Assoc Study Obes. 2020;21(5):e12988.
doi: 10.1111/obr.12988
Angeles PC, Robertsen I, Seeberg LT, et al. The influence of bariatric surgery on oral drug bioavailability in patients with obesity: a systematic review. Obes Rev Off J Int Assoc Study Obes. 2019;20(9):1299–311.
doi: 10.1111/obr.12869
Busetto L, Dicker D, Azran C, et al. Obesity management task force of the European Association for the study of obesity released “Practical Recommendations for the Post-Bariatric Surgery Medical Management”. Obes Surg. 2018;28(7):2117–21.
doi: 10.1007/s11695-018-3283-z
Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J. sept. 2008;42(5):409–19.
doi: 10.1177/009286150804200501
Hamad GG, Helsel JC, Perel JM, et al. The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry. mars. 2012;169(3):256–63.
doi: 10.1176/appi.ajp.2011.11050719
Lloret-Linares C, Hirt D, Bardin C, et al. Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach. Clin Pharmacokinet. 2014;53(10):919–30.
Lebowitz D, Juillet C, Kehtari R. Nutritional deficiency after gastric bypass surgery: a review of the literature and guidelines for follow-up. Rev Med Suisse. 2012;8(333):649–54.
pubmed: 22506449
Ko B-J, Myung SK, Cho K-H, et al. Relationship between bariatric surgery and bone mineral density: a meta-analysis. Obes Surg. 2016;26(7):1414–21.
doi: 10.1007/s11695-015-1928-8
Raschi E, Poluzzi E, Salvo F, et al. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr Metab Cardiovasc Dis NMCD. 2018;28(6):533–42.
doi: 10.1016/j.numecd.2018.02.014